Description

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual and Recell Ice for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method; and Careveam for treating skin ailment by using ultraviolet light. Further, the company offers Neurakin cream for acute eczema, contact dermatitis, atopic dermatitis, chronic eczema, rosacea dermatitis, perioral dermatitis, herpes zoster, and acne vulgaris. It also exports its products to approximately 60 countries, including Japan, Thailand, and Brazil. Medytox, Inc. has partnership with Dyadic International, Inc. to develop vaccines against COVID-19 variants. The company was founded in 2000 and is headquartered in Cheongju, South Korea.